Last Week Tonight in BioPharma: March 28th - April 3rd

FOUNDAYO, oral PCSK9, big deals from LIlly and Biogen, plus Trump is at it again with tariffs

Apr 5 • Big Pharma Sharma

4

2

Biogen’s Great Molt is Complete

Having shed its legacy Multiple Sclerosis shell, the company emerges with a hardened focus on Rare Disease and Immunology, solidified by the Apellis…

Apr 2 • Big Pharma Sharma

4

1

March 2026

Last Week Tonight in BioPharma: March 20th - 27th

The first edition of a new weekly offering for BPS subscribers - hope you enjoy it!

Mar 29 • Big Pharma Sharma

7

2

2

Reclaiming the Narrative: What BioPharma Must Learn From Tech Before It's Too Late

Our story is slipping. Tech knows how to tell one. Here's what we need to adopt to tell our story.

Mar 26 • Big Pharma Sharma

4

2

Who's Actually Earning Their Seat at the Table?

A Data-Driven Scorecard of Big Pharma CEO Performance

Mar 11 • Big Pharma Sharma

6

2

1

February 2026

Drug Dealin Ep. 9: Using AI to Find Novel Treatment Options

How the average person can use clinicaltrials.gov and AI tools to find better care

Feb 26 • Big Pharma Sharma

3

1

34:48

Why Gilead Really Bought Arcellx

Does this mean autologous cell therapy is back in favor? Not quite.

Feb 24 • Big Pharma Sharma

7

4

3

The FDA Decision That Just Setback America's mRNA Vaccine Industry

The far reaching implication of Vinay Prasad's unprecedented refusal-to-file letter for Moderna's flu shot

Feb 13 • Big Pharma Sharma

4

2

January 2026

Drug Dealin Ep. 8: 2026 Predictions

Kenny and I grade our 2025 predictions and share our predictions for 2026

Jan 29 • Big Pharma Sharma

3

3

59:35

Big Pharma at JPM 2026: M&A, Obesity, and China

How patent cliffs are dividing Big Pharma's M&A approach, plus obesity market battles, direct-to-consumer shifts, and China's innovation role

Jan 22 • Big Pharma Sharma

11

2

Six Biotechs Getting Acquired in 2026

Ahead of JPM, here are the six companies I think will be acquired by the end of the year

Jan 9 • Big Pharma Sharma

16

6

December 2025

ASH 2025: Is This the Beginning of the End for Autologous CAR-T in Multiple Myeloma?

MajesTEC-3's historic efficacy, Kelonia's clean in vivo data, and Prasad's new superiority requirements create a perfect storm

Dec 10, 2025 • Big Pharma Sharma

8

2

3